Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01144507
Other study ID # CFLD PUSH
Secondary ID U01DK062456
Status Completed
Phase
First received
Last updated
Start date January 12, 2010
Est. completion date June 14, 2023

Study information

Verified date October 2023
Source National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The specific aims for this study are: 1. To determine if sonographic findings predict the risk of progression of liver disease to cirrhosis by comparing cystic fibrosis subjects with heterogeneous echogenicity pattern on ultrasound to those with normal echogenicity pattern on ultrasound 2. To develop a database and biorepository of serum, plasma, urine and DNA to aid the investigations in ascertaining the mechanisms, consequences, genetic risk factors and biomarkers for the development of cirrhosis 3. To determine if there are differences in health related quality of life, pulmonary or nutritional status in children with cystic fibrosis who have a heterogeneous echo pattern on ultrasound compared to those who have a normal echo pattern on ultrasound 4. To determine if Doppler velocity measurements of hepatic and splenic vessels predict an increased risk for the development of cirrhosis. 5. To determine if cirrhosis on ultrasound progresses to portal hypertension during the study period 6. To determine if homogeneous liver progresses to either cirrhosis or heterogeneous liver. 7. To determine the frequency of complications of portal hypertension during follow up in those identified with cirrhosis by year 6 of the study


Description:

For subjects in longitudinal follow up, this study will: 1. Collect detailed clinical and demographic information about each subject at enrollment and during follow up, 2. Obtain and store imaging data from the subject at entry and during follow up, 3. Obtain and store serum, plasma and urine samples from the subject at entry (after matching) and during follow up, 4. Obtain and store DNA from the subject, 5. Obtain and store DNA from the biological parents, 6. Obtain and store quality of life data from the subject and parents at enrollment and during follow up


Recruitment information / eligibility

Status Completed
Enrollment 774
Est. completion date June 14, 2023
Est. primary completion date February 26, 2021
Accepts healthy volunteers No
Gender All
Age group 3 Years to 12 Years
Eligibility Inclusion Criteria: - Children aged 3 through 12 years of age at time of enrollment diagnosed with Cystic Fibrosis and pancreatic insufficiency - Enrolled in the CFF registry study or Toronto CF Registry - CF defined as sweat chloride of >60 mEq/L on one occasion (using the value in the CF registry) or two disease-causing mutations of CFTR with evidence of end organ involvement. - Pancreatic insufficient defined as one of the following: - CFTR Mutation associated with pancreatic insufficiency - Fecal elastase <100 mcg/gm (at any time) - 72 hour fecal fat with coefficient of fat absorption <85% (at any time) Exclusion Criteria: - Known cirrhosis - Presence of Burkholderia cepacia - Short bowel syndrome defined as not on full enteral feeds by 3 months of age - Presence of other serious disease precluding participation in this study (This would include patients with known other causes of chronic liver disease) - If in the opinion of the Investigator the study is not in the best interest of the patient - Inability to comply with the longitudinal follow-up described below - Failure of a family to sign the informed consent document or the HIPAA medical record release form

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Abdominal Ultrasound
To establish eligibility and/or markers regarding echo pattern types.
Other:
Sample collection procedures
Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects

Locations

Country Name City State
Canada Hospital for Sick Children Toronto Ontario
United States Emory University School of Medicine Atlanta Georgia
United States Children's Hospital of Colorado Aurora Colorado
United States Johns Hopkins School of Medicine Baltimore Maryland
United States Ann & Robert H. Lurie Children's Hospital of Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Texas Children's Hospital Houston Texas
United States Riley Hospital for Children Indianapolis Indiana
United States University of Minneapolis Medical Center Minneapolis Minnesota
United States Washington University School of Medicine Saint Louis Missouri
United States Seattle Children's Hospital Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Cystic Fibrosis Foundation

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Development of cirrhosis, as defined by imaging criteria The primary objective of this prospective longitudinal study is to determine the utility of abdominal ultrasound (US) at enrollment to predict the development of cirrhosis in subjects with cystic fibrosis (CF) within a nine year period. Nine years
Secondary Effects on associated pulmonary and nutritional issues Health related quality of life
Growth (length, weight and BMI Z-score, anthropometrics)
AST,ALT,GGTP
FEV1, FVC
Sputum Culture (Pseudomonas, Burkholderia cepacia)
Use of IV antibiotics
Hospitalization for treatment of pulmonary exacerbation
CBC (WBC, Hbg, ANC, platelet count)
Fat soluble vitamin levels (Vitamin E, 25 hydroxy vitamin D, Vitamin A)
9years
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A